Virios therapeutics announces exploratory long-covid trial top-line data, featuring combination of valacyclovir and celecoxib, projected in june 2023

Atlanta, feb. 13, 2023 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“fm”), announced today that it expects top-line results from its phase 2 post-acute sequelae of covid-19 (also known as pasc or long-covid) exploratory clinical trial to be available in june 2023. this study will assess the potential of the antiviral combination of valacyclovir and celecoxib to provide symptomatic improvements in patients suffering from long-covid when added to standard of care therapy. outcomes being assessed in this study include fatigue, sleep, attention, pain, autonomic function, memory and anxiety.
VIRI Ratings Summary
VIRI Quant Ranking